April 2, 2025 02:36 PM EDT
Pharma
Law

FTC's fight against PBMs is paused

Nicole DeFeudis

Editor

The FTC’s le­gal fight against three ma­jor phar­ma­cy ben­e­fit man­agers is on hold af­ter two agency com­mis­sion­ers have been re­moved by the Trump Ad­min­is­tra­tion. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Chaot­ic tar­iff roll­out leaves as many ques­tions as an­swers for drug­mak­ers

Trump’s broad tar­iffs ex­empt phar­ma — but for how long?

Sarep­ta, Roche pause Ele­v­idys tri­als in Eu­rope fol­low­ing pa­tient death

Day af­ter mass FDA fir­ings, new com­mis­sion­er ad­dress­es re­main­ing staff, fo­cus­ing on 'MA­HA' vi­sion

Ex­clu­sive: Neu­rona bags $102M to treat epilep­sy with cell ther­a­py

sponsored

End­points we­bi­nar: In­side the “One Lon­za” strat­e­gy: Re-en­gi­neer­ing the fu­ture of CD­MO

A service from the Financial Times